|
|
Volumn 103, Issue 6, 2011, Pages 455-457
|
|
Accelerated drug approval: FDA may get tougher; companies cite hurdles.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CELECOXIB;
CETUXIMAB;
MONOCLONAL ANTIBODY;
NEW DRUG;
PANITUMUMAB;
PYRAZOLE DERIVATIVE;
SULFONAMIDE;
ADVISORY COMMITTEE;
CONTROLLED CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG INDUSTRY;
EUROPE;
EVIDENCE BASED MEDICINE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METHODOLOGY;
NOTE;
UNITED STATES;
ADVISORY COMMITTEES;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CONTROLLED CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, INVESTIGATIONAL;
EUROPE;
EVIDENCE-BASED MEDICINE;
HUMANS;
PYRAZOLES;
SULFONAMIDES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79955735368
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr087 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
